SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: a case report

Acta Diabetol. 2022 Oct;59(10):1391-1394. doi: 10.1007/s00592-022-01909-9. Epub 2022 Jun 19.

Enzo Secinaro^{1

2}, Simone Ciavarella^{1

2}, Giulia Rizzo^{1

2}, Ettore Porreca^{1

2}, Ester Vitacolonna^{3

4

5}

¹ Department of Innovative Technologies in Medicine and Dentistry, School of Medicine, and Health Sciences, "G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy.
² Division of Internal Medicine, Department of Internal Medicine, SS Annunziata Hospital-Chieti, Chieti, Italy.
³ Division of Internal Medicine, Department of Internal Medicine, SS Annunziata Hospital-Chieti, Chieti, Italy. e.vitacolonna@unich.it.
⁴ Diabetes, Nutrition and Metabolic Diseases Unit, SS Annunziata Hospital-Chieti, Chieti, Italy. e.vitacolonna@unich.it.
⁵ Department of Medicine and Ageing Sciences, "G. D' Annunzio" University of Chieti-Pescara, Chieti, Italy. e.vitacolonna@unich.it.

No abstract available

Keywords: COVID-19; Euglycemic diabetic ketoacidosis; LADA; Low-carbohydrate intake; SGLT2-inhibitors.

Publication types